Alnylam Pharmaceuticals Income Statement (2009-2026) | ALNY

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	220.55M	187.63M	258.54M	213.26M	224.82M	264.31M	335.04M	319.29M	318.75M	750.53M	439.72M	494.33M	659.83M	500.92M	593.17M	30.00M	773.69M	1,249.03M	1,097.03M	1,167.17M
Cost of Revenue (Quarter)	30.26M	28.09M	33.63M	23.46M	34.04M	36.51M	46.17M	41.43M	75.34M	79.47M	71.97M	54.61M	67.27M	81.98M	102.65M	70.18M	142.03M	197.23M	267.72M	207.52M
Gross Profit (Quarter)	190.30M	159.54M	224.90M	189.80M	190.78M	227.80M	288.86M	277.86M	243.42M	671.06M	367.74M	439.72M	592.55M	418.94M	490.52M	-40.18M	631.66M	1,051.80M	829.31M	959.65M
Operating items
Research & Development (Quarter)	182.63M	194.57M	229.05M	169.89M	205.71M	245.37M	262.04M	230.57M	248.53M	253.18M	272.14M	261.00M	294.14M	270.93M	300.17M	265.12M	323.62M	358.81M	372.22M	364.87M
Selling, General & Administrative (Quarter)	145.32M	142.07M	186.38M	154.47M	169.98M	235.86M	210.34M	183.66M	214.69M	199.18M	198.12M	210.80M	248.40M	220.99M	295.34M	239.95M	323.31M	322.08M	325.37M	322.55M
Other Operating Expenses (Quarter)	38.76M	32.66M	37.66M	35.63M	40.81M	41.12M	51.27M	54.87M	85.37M	84.31M	85.86M	65.98M	68.67M	85.91M	102.82M	71.04M	142.95M	200.15M	267.72M	211.12M
Operating Expenses (Quarter)	366.71M	369.31M	453.10M	359.99M	416.50M	522.35M	523.65M	469.10M	548.59M	536.66M	556.12M	537.77M	611.21M	577.82M	698.33M	576.11M	789.89M	881.04M	965.32M	898.54M
Operating Income (Quarter)	-146.16M	-181.68M	-194.56M	-146.73M	-191.69M	-258.04M	-188.61M	-149.81M	-229.83M	213.87M	-116.40M	-43.44M	48.61M	-76.91M	-105.16M	18.08M	-16.20M	367.98M	131.72M	268.64M
EBIT (Quarter)	-146.16M	-181.68M	-194.56M	-146.73M	-191.69M	-258.04M	-188.61M	-149.81M	-229.83M	213.87M	-116.40M	-43.44M	48.61M	-76.91M	-105.16M	18.08M	-16.20M	367.98M	131.72M	268.64M
Non-operating items
Interest & Investment Income (Quarter)	0.41M	0.23M	0.49M	1.01M	1.90M	7.82M	14.08M	18.66M	21.07M	25.43M	30.41M	29.64M	29.18M	32.15M	31.02M	28.67M	27.49M	28.68M	26.63M	26.60M
Other Non Operating Income (Quarter)	-8.76M	17.71M	-28.45M	-51.27M	-42.28M	-76.60M	55.02M	-12.26M	-35.42M	-57.66M	-20.35M	-14.54M	-55.70M	-29.53M	-80.85M	9.19M	-6.40M	-74.15M	-3.36M	-4.29M
Non Operating Income (Quarter)	-42.17M	17.71M	-171.95M	-92.62M	-82.99M	-38.05M	189.34M	-22.55M	-44.38M	-57.66M	-20.35M	-20.15M	-55.70M	-31.76M	-88.80M	9.19M	-19.16M	-74.15M	138.17M	-46.98M
Net income details
EBT (Quarter)	-188.33M	-204.24M	-260.30M	-239.36M	-274.67M	-405.94M	-207.02M	-172.36M	-274.21M	150.74M	-137.69M	-63.59M	-11.17M	-108.66M	-193.96M	-2.37M	-35.36M	280.57M	86.26M	221.65M
Tax Provisions (Quarter)	1.23M	0.28M	-1.84M	0.98M	2.73M	-0.02M	0.47M	1.74M	1.81M	2.99M	0.18M	2.35M	5.72M	2.91M	-110.19M	15.88M	30.92M	-12.12M	-25.28M	15.66M
Profit After Tax (Quarter)	-189.56M	-204.51M	-258.46M	-240.34M	-277.40M	-405.92M	-207.49M	-174.10M	-276.02M	147.75M	-137.87M	-65.94M	-16.89M	-111.57M	-83.76M	-18.25M	-66.28M	251.08M	111.54M	205.99M
Equity Income (Quarter)
Income from Continuing Operations (Quarter)	-189.56M	-204.51M	-258.46M	-240.34M	-277.40M	-405.92M	-207.49M	-174.10M	-276.02M	147.75M	-137.87M	-65.94M	-16.89M	-111.57M	-83.76M	-18.25M	-66.28M	292.68M	111.54M	205.99M
Consolidated Net Income (Quarter)	-189.56M	-204.51M	-258.46M	-240.34M	-277.40M	-405.92M	-207.49M	-174.10M	-276.02M	147.75M	-137.87M	-65.94M	-16.89M	-111.57M	-83.76M	-18.25M	-66.28M	292.68M	111.54M	205.99M
Income towards Parent Company (Quarter)	-189.56M	-204.51M	-258.46M	-240.34M	-277.40M	-405.92M	-207.49M	-174.10M	-276.02M	147.75M	-137.87M	-65.94M	-16.89M	-111.57M	-83.76M	-18.25M	-66.28M	292.68M	111.54M	205.99M
Net Income towards Common Stockholders (Quarter)	-189.56M	-204.51M	-258.46M	-240.34M	-277.40M	-405.92M	-207.49M	-174.10M	-276.02M	147.75M	-137.87M	-65.94M	-16.89M	-111.57M	-83.76M	-18.25M	-66.28M	292.68M	111.54M	205.99M
Additional items
EPS (Basic) (Quarter)	-1.61	-1.72	-2.16	-2.00	-2.29	-3.32	-1.68	-1.40	-2.21	1.18	-1.09	-0.52	-0.13	-0.87	-0.65	-0.14	-0.51	1.91	0.84	1.55
EPS (Weighted Average and Diluted) (Quarter)	-1.61	-1.72	-2.16	-2.00	-2.29	-3.32	-1.68	-1.40	-2.21	1.15	-1.09	-0.52	-0.13	-0.87	-0.65	-0.14	-0.51	1.84	0.82	1.51
Shares Outstanding (Weighted Average) (Quarter)	117.77M	118.00M	118.45M	120.39M	120.65M	122.17M	121.69M	124.11M	124.39M	124.67M	124.91M	126.14M	126.44M	128.59M	127.65M	129.68M	130.63M	131.45M	131.00M	132.89M
Shares Outstanding (Diluted Average) (Quarter)	117.77M	119.14M	118.45M	120.39M	120.90M	122.17M	121.69M	124.11M	124.66M	124.67M	124.91M	126.14M	126.44M	127.16M	127.65M	129.68M	130.16M	134.15M	134.68M	138.23M
EBITDA (Quarter)	-188.92M	-202.66M	-257.49M	-245.15M	-281.56M	-407.48M	-208.36M	-168.57M	-273.98M	152.49M	-128.91M	-69.55M	-24.54M	-101.76M	-93.45M	-21.25M	-58.71M	259.26M	113.22M	201.19M
Interest Expenses (Quarter)	33.42M	40.27M	36.82M	42.36M	42.61M	41.08M	29.91M	28.95M	30.04M	30.89M	31.34M	35.25M	33.26M	34.38M	38.97M	58.31M	40.25M	44.40M	65.40M	69.29M
Tax Rate (Quarter)	-0.65%	-0.14%	0.71%	-0.41%	-0.99%	0.01%	-0.23%	-1.01%	-0.66%	1.98%	-0.13%	-3.69%	-51.24%	-2.68%	56.81%	-670.73%	-87.45%	-4.32%	-29.31%	7.07%

Research Tools

Alnylam Pharmaceuticals Income Statement (2009-2026) | ALNY

Create an account

Sign In

Reset Password